Description: Rhinomed Limited, a medical technology company, researches, develops, and commercializes consumer and medical devices. The company identifies, acquires, and commercializes late stage therapeutic delivery technologies. It markets Turbine, a nasal dilator designed to assist to breathe easier during aerobic exercise; and Mute, a nasal dilator designed to enhance sleep quality by breathing more and snoring less. The company also develops Breathing Space Health that comprises of a range of wellness programs designed to help people get to sleep. In addition, it develops Sleep Apnea, a clinical trial solution to mild and moderate sleep apnea; creates drug delivery platform for delivering medication into the nose in an inhaled form or via a trans-dermal or trans-mucosal method; and researches and develops current programs focuses on olfactory pathway and wearable technology. The company sells its products through wholesalers, retail stores, and clinics, as well as online in the United States, Canada, the United Kingdom, Taiwan, Australia, and New Zealand. It serves clinicians and health care organizations. The company was formerly known as Consegna Group Limited and changed its name to Rhinomed Limited in November 2013. Rhinomed Limited was incorporated in 2004 and is based in Cremorne, Australia.
Home Page: www.rhinomed.global
132 Gwynne Street
Cremorne,
VIC
3121
Australia
Phone:
61 3 8416 0900
Officers
| Name | Title |
|---|---|
| Mr. Michael Johnson | CEO, MD & Exec. Director |
| Mr. Sean Slattery | CFO & Company Sec. |
Exchange: OTCQB
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 5.8625 |
| Price-to-Sales TTM: | 2.2085 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |